J. Obst

发表

Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants

R. Andersen, M. Sadar, Jun Wang, 2020, Cancers.

Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1

M. Sadar, Jun Wang, N. Mawji, 2022, Cancers.

Developing Inhibitors to the Amino-Terminus Domains of Steroid Hormone Receptors

M. Sadar, A. H. Tien, J. Obst, 2021, Nuclear Receptors.

Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies.

David E. Williams, R. Andersen, M. Sadar, 2019, ACS pharmacology & translational science.

A model of acquired resistance to the novel AR-NTD inhibitor ralaniten reveals resistance occurs via a selective metabolism pathway

J. Obst, 2018 .

Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.

R. Andersen, M. Sadar, K. Chi, 2019, Journal of Clinical Oncology.

Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation.

M. Sadar, J. Obst, 2016, Translational cancer research.

Rational optimization of a transcription factor activation domain inhibitor

Paul Robustelli, X. Salvatella, Denes Hnisz, 2023, Nature structural & molecular biology.

Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer

M. Sadar, J. Obst, A. Tien, 2024, Steroids.